{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"ORR defined as the number of participants demonstrating complete response or partial response. Complete response defined as complete disappearance of an M-protein and no evidence of MM in the bone marrow. Partial response defined as ≥50% reduction in the level of the serum monoclonal paraprotein, reduction in 24-hour M-protein either by greater than or equal to 90% or to \\<200 mg, ≥50% reduction in size of soft tissue plasmacytoma (by radiography or clinical examination), no increase in the number or size of lytic bone lesions.","groups":[{"description":"First participant received: CFZ 27mg/m\\^2, Bendamustine 70mg/m\\^2, Dexamethasone 20mg; Second participant received: CFZ 36mg/m\\^2, Bendamustine 70mg/m\\^2, Dexamethasone 20mg; Third participant received: CFZ 36mg/m\\^2, Bendamustine 90mg/m\\^2, Dexamethasone 20mg; Fourth participant received: CFZ 45mg/m\\^2, Bendamustine 90mg/m\\^2, Dexamethasone 20mg; Fifth participant and all other participants received: CFZ 56mg/m\\^2, Bendamustine 90mg/m\\^2, Dexamethasone 20mg.\n\nData was collected and analyzed as one arm for this single-arm study. Additionally, presented as one arm to protect the confidentiality of the first four participants.","id":"OG000","title":"CFZ With Bendamustine and Dexamethasone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"participants"}